The NIMH-CATIE Schizophrenia Study: what did we learn?

Am J Psychiatry. 2011 Aug;168(8):770-5. doi: 10.1176/appi.ajp.2011.11010039.
No abstract available

Publication types

  • Comparative Study

MeSH terms

  • Antipsychotic Agents / adverse effects
  • Antipsychotic Agents / economics
  • Antipsychotic Agents / therapeutic use*
  • Chronic Disease
  • Cost-Benefit Analysis
  • Drug Costs
  • Drug Substitution
  • Humans
  • Marketing / economics
  • Medication Adherence
  • Patient Dropouts
  • Perphenazine / adverse effects
  • Perphenazine / economics
  • Perphenazine / therapeutic use
  • Randomized Controlled Trials as Topic
  • Schizophrenia / diagnosis
  • Schizophrenia / drug therapy*
  • Schizophrenia / economics
  • Schizophrenic Psychology*
  • United States

Substances

  • Antipsychotic Agents
  • Perphenazine